Innovation And Optimisation To Improve Medicines Access
Associate Health Minister David Seymour has today announced more clear expectations for Pharmac to innovate and optimise to further build on expectations set last year; to deliver the medicines and medical technology that Kiwis need.
'Increasing medicines access is one of my greatest priorities. For many New Zealanders, funding for pharmaceuticals is life or death, or the difference between a life of pain and suffering or living freely,' Mr Seymour says.
Since my last letter of expectations Pharmac has:
Improved overall consultation
Added additional consultation to the annual tender process
Changed funding criteria based on public feedback, such as the decision to fund two types of oestradiol patches
Appointed Natalie McMurtry as the incoming Chief Executive to cement positive change, and continue to move towards a more transparent, inclusive, and people-focused organisation
Conducted, and published a report on, the Consumer Engagement Workshop to help reset the Patient-Pharmac relationship
Appointed a Consumer Working Group to help reset the Patient-Pharmac relationship
Funded access to 66 additional medicines using the Government's $604 million budget boost over four years which will benefit over 200,000 New Zealanders
'This is a good start. My letter of expectations for this year makes it very clear that there is still more work to be done. I expect this positive culture shift to continue,' Mr Seymour says.
'Pharmac must modernise, or it will fall behind. It needs to adopt faster, smarter processes and explore the use of AI to lift performance.'
My expectations for this year are that Pharmac should:
Explore how it can optimise medicines assessment and procurement processes to make them more efficient
Explore ways to utilise AI to make their processes more efficient
Consider the fiscal impacts to the government of funding medicines and medical devices, including costs of societal impacts of funding or not funding a medicine or medical device
Be more proactive in engaging with stakeholders
Look for new and additional funding opportunities for medicines and medical devices
Publish measurable performance metrics and timely decisions to increase transparency
Continue to involve patients early in the process and engage with them meaningfully
'We're committed to ensuring that the regulatory system for pharmaceuticals is not unreasonably holding back access. It will lead to more Kiwis being able to access the medicines they need to live a fulfilling life,' Mr Seymour says.
'I am looking forward to continuing to work with Pharmac as we continue to ensure Kiwis get timely access to medicines and medical devices.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NZ Herald
3 hours ago
- NZ Herald
Helius and Elysian to continue merger after Cannabis Clinic withdrawal
'I think these things happen when you're looking at mergers and going through that process, you get to learn more about how the entire structure would work, about each other's cultures and how we approach things, we understand more about each other's businesses as well,' Alzaher said. 'That's why we mutually agreed and reached the conclusion that it would be better for us to work independently.' Dr Waseem Alzaher, CEO and co-founder of the Cannabis Clinic, says it will be better for the businesses to work independently towards their shared goal. Alzaher said the proposal had been spoken about between the parties for about two months before the announcement to the public. After a further three weeks deep-diving on the proposal and deciding on how it would work, the decision was made for it not to proceed. Alzaher said the decision to communicate proactively about the proposal was because of Helius Therapeutics' shareholders and its responsibility to keep them involved, and he said he would do the process the same if given another opportunity. 'We're still open to partnerships, to collaboration, to investment, to coming together, so that one plus one equals 10. 'The bigger picture for us is revolutionising healthcare, how healthcare is delivered, the systems, the expectations, how it's centred around people. 'That's a big mission. Our big area audacious goal is to have a million long-term clients with us, and that's not going to happen overnight.' As for what didn't work between Cannabis Clinic and Helius Therapeutics, Alzaher said that their business cultures and visions were not necessarily aligned. He viewed Cannabis Clinic as a 'rebel' and a 'misfit' trying to disrupt the system, and said the business' time could be better spent helping more Kiwis instead. Alzaher said he could see the businesses working together in the future, although not in the 'foreseeable future'. 'With Helius they've got products that are New Zealand made and we're still distributing them. We see them as a strategic partner for us moving forward. 'They believe in what we're doing, we believe in what they're doing, and we're still talking to each other and on good terms.' Helius Health chairman Guy Haddleton previously said the industry long needed a reset. Photo / File Merger moves on Despite the mutual decision for Cannabis Clinic to pull out of the proposed merger, Helius Therapeutics and Elsyian Group/CannaPlus have confirmed a two-way merger will now take its place. Helius Therapeutics financial officer Bruce McEwen said the businesses expect to settle in August. 'What happens now – it's full steam ahead with the execution of the new strategy and the merger with CannaPlus," McEwen said. 'Whilst it's now a two not three-way merger and reduces overall scale, it doesn't change the direction or effectiveness of the strategy. It does however make it simpler, enabling us to move faster.' McEwen said Helius Therapeutics shareholders were firmly behind the strategy pivot to vertically integrate and the proposed two-party merger. He said Helius Therapeutics and Cannabis Clinic had a strong mutual respect for each other and continued to be key business partners. 'After careful consideration we mutually agreed not to proceed with the proposed merger between Helius Therapeutics and Cannabis Clinic. 'Whilst there is strong alignment around increasing access to medicinal cannabis and reducing the stigma, we agreed that was better achieved independently.' Helius Health chairman Guy Haddleton was unavailable for comment. Elysian executive chairwoman Eva Piëch said the fundamentals of the transaction remained intact. 'The transition to a two-party merger between Elysian and Helius is a deliberate and strategically focused decision. It enhances clarity, accelerates execution, and strengthens alignment – not only operationally, but philosophically,' Piëch said. 'This structure allows for faster execution, clearer governance and greater strategic clarity. Our infrastructure, patient network and digital platform remain core to the combined strategy.' Piëch said that as discussions matured with Cannabis Clinic, it became clear a three-party integration would introduce operational complexity and dilute strategic focus – without materially strengthening the core proposition. She said the two-party plan would preserve strategic coherence and allow the pair to integrate with speed, purpose and precision. 'This two-way merger creates a clean, tightly aligned platform – one that enables rapid integration, strategic coherence and a stronger foundation for long-term innovation and growth.' Tom Raynel is a multimedia business journalist for the Herald, covering small business, retail and tourism.
Scoop
4 hours ago
- Scoop
New PHANZ Policy Affirms The Importance Of Community Water Fluoridation
The Public Health Association of New Zealand (PHANZ) supports community water fluoridation as a critical public health measure and supports the Government continuing to uphold its responsibility for implementing community water fluoridation. Releasing its new policy position statement on Community Water Fluoridation, the PHANZ emphasises the strong body of international and national evidence supporting community water fluoridation as a safe and effective public health measure for preventing tooth decay in both children and adults. 'Fluoridated water protects our mokopuna, whānau and communities who might face barriers in accessing dental care' says Dr Cadence Kaumoana, Chief Executive. 'It is a simple, safe, proven and equitable approach to improve the oral health of all people in Aotearoa New Zealand.' In Aotearoa New Zealand, tooth decay is one of the leading causes of hospital admissions for children aged 0-14 years. In 2019, there were 9,267 dental and hospital events, equating to 4.6% of all children's hospital events, and tooth decay was the most common principal diagnosis (7,161 children) from all children's hospital events.[1]For adults (aged 15 years and over), 45.0% have had one or more teeth removed in their lifetime due to tooth decay, with increased prevalence for Māori (50.3%) and people with disabilities (64.4%).2 Until relatively recently, the decision to fluoridate water supplies was determined at a local authority level. However, the introduction of the Health (Fluoridation of Drinking Water) Amendment Act 2021[ 3] enabled the Director-General of Health to direct local authorities to fluoridate drinking water supplies, creating a nationally consistent, health-focused, and evidence-based decision-making process for community water fluoridation in Aotearoa New Zealand. In July 2022, the Director-General of Health issued directions to 14 local authorities to take practicable steps (with support from the Ministry of Health) to ensure their drinking water supplies contained optimal level of fluoride.[4] As a result of the directions to these 14 local authorities, around 400,000 more people have gained access to fluoridated community drinking water.[5] The PHANZ notes that despite the overwhelming evidence for community water fluoridation, and the public health benefits of centralising decision-making under the Director-General of Health, opposition to this approach persists. In February 2025, a Member's Bill from New Zealand First proposed repealing the Health (Fluoridation of Drinking Water) Amendment Act 2021.[6] Repealing this would return responsibility for fluoridation to local authorities, a system that previously led to regional inconsistencies and allowed misinformation and non-evidenced-based decisions to compromise oral health outcomes. In response to this announcement, the Health Minister reaffirmed that the Government would maintain its current fluoride policy.7 'Oral health isn't just about teeth — it's about dignity, confidence, and basic quality of life,' says Dr Kaumoana. 'We support the Government's commitment to keep community water fluoridation at the national level. Every whānau deserves access to safe and effective oral health protection regardless of their location. This is a simple, proven way to prevent harm and reduce health inequities.' The PHANZ also recognises that oral health is shaped by a broad range of social determinants. While our recent statement focuses on community water fluoridation, it should be understood within the wider oral health context in Aotearoa New Zealand, including the impacts of childhood poverty, food insecurity, unhealthy food environments, and the unmet demand, and barriers to access, for oral health care across the health system. Improving oral health in Aotearoa New Zealand requires coordinated, cross-sector action, of which community water fluoridation is an important component. • Read the full PHANZ policy position statement: PHANZ Policy Position Statement on Community Water Fluoridation • Watch the PHANZ policy webinar supporting the release of the policy position statement. This webinar includes a brief overview of the policy position statement, followed by a presentation from oral health expert and PHANZ member Heuiwon (Chris) Han. About the Public Health Association of New Zealand The Public Health Association of New Zealand is a non-profit organisation dedicated to promoting health and well-being in Aotearoa. Comprising a diverse membership, including health professionals, academics, and advocates, the PHA strives to influence policies and practices that address the social determinants of health and advance equitable health outcomes. Visit for more information on our organisation and our Council members. Note: 1 Ministry of Health Manatū Hauora. (2021). Publicly funded hospital discharges – 1 July 2018 to 30 June 2019. Wellington: Ministry of Health. july-2018-to-30-june-2019 2 Ministry of Health Manatū Hauora. (2024). Annual data explorer 2023/24: New Zealand health survey [Data File]. 3 4 community-water-fluoridation 5 fluoridated-drinking-water 6
Scoop
11 hours ago
- Scoop
Lobbying Docs Show Govt's Weakness
Today's revelations of tobacco industry lobbying lay bare why Labour's Tobacco Transparency Bill is needed to stop governments putting the interests of the industry above people's health. Today's RNZ story shows the wide range of politicians, experts, and officials tobacco lobbyists Philip Morris targeted to influence regulations and garner support for their products, including targeting Winston Peters. 'Christopher Luxon's weak leadership has allowed Winston Peters and the tobacco industry ride roughshod over him by agreeing to a $200 million tax break for the tobacco industry,' Labour health spokesperson Ayesha Verrall said. 'Philip Morris even wrote legislation for NZ First to loosen the regulations around vaping. They note that Winston Peters is 'industry friendly and highly geared towards commercial interests in the sector. 'I launched a members' bill earlier this year to require disclosure of government contact with the tobacco industry, to make sure industry efforts to undermine New Zealanders' health are reported,' Ayesha Verrall said. The documents revealed today also show how vaping company JUUL targeted New Zealand as a market. 'It's gutting to think we might not have the youth vaping problem we have today if my Bill was in place in 2018 before any of this lobbying took place. 'Around the world, tobacco companies have a long history of influencing and weakening health policies to better suit their bottom line – and here we see evidence of it happening in New Zealand. 'It's time we get rid of the smokescreen and protect Kiwis from big tobacco's lobbying tactics – they have no place in health policy,' Ayesha Verrall said.
